Minaris Regenerative Medicine is proud to share current and past news and announcements from its over twenty years of experience. Please see below for our press releases and announcements.

*This page may include mention of our past company names as it reflects content distributed in the past. The former companies Hitachi Chemical Advanced Therapeutics Solutions (HCATS, formerly PCT or PCT Cell Therapy Services) and apceth Biopharma GmBH are now operating under the name Minaris Regenerative Medicine. Hitachi Chemical Co., Ltd. has been renamed Showa Denko Materials Co., Ltd.
September 23, 2020

Hitachi Chemical's Global Regenerative Medicine Business Renamed Minaris Regenerative Medicine

Allendale, NJ., USA, Munich, Germany, and Yokohama, Japan-Sept. 23, 2020-The regenerative medicine business of Hitachi Chemical Co., Ltd. (“Hitachi Chemical”) announces that, effective today, it has adopted the name Minaris Regenerative Medicine to represent its global contract development and manufacturing services business for the cell and gene therapy industry. “By working and using the single ...

May 11, 2020

Hitachi Chemical Advanced Therapeutics Solutions and apceth Biopharma GmbH Enter into Strategic Clinical and Commercial Manufacturing Agreements with bluebird bio

 ALLENDALE, NJ. and MUNICH, GERMANY.-- May 11, 2020-- Hitachi Chemical Advanced Therapeutics Solutions, LLC (HCATS) and apceth Biopharma GmbH (apceth), both subsidiaries of Hitachi Chemical Co., Ltd. (Hitachi Chemical), today announced that they have expanded their relationship with bluebird bio (NASDAQ: BLUE) with long-term development and manufacturing services agreements for clinical and ...

April 10, 2020

Continuing to Navigate COVID-19 Together

The entire team at HCATS continues its commitment to stay ahead of and respond to the COVID-19 situation. At this time, our facilities continue operations and all our amazing employees are working exceptionally hard through these challenging circumstances to provide our clients with the high-quality support they are accustomed to and deserve. Although both Bergen County, New Jersey and Santa ...

March 18, 2020

Navigating COVID-19 at HCATS

At HCATS, we are dedicated to providing our clients with high value development and manufacturing services while fostering a safe environment that does not put our patients, clients, or employees at risk. Due to this and the growing concern of COVID-19, we are taking necessary precautions and implementing new policies and procedures so we can continue to work toward making transformative ...

January 30, 2020

Hitachi Chemical Opens New Cell and Gene Therapy Manufacturing Facility

Company Expects to Add Up to 500 Employees in New Jersey Hitachi Chemical Advanced Therapeutics Solutions, LLC (“HCATS”), a subsidiary of Hitachi Chemical Co., Ltd. representing Hitachi Chemical’s Regenerative Medicine Business Sector (“RMBS”) in North America, today announced the opening of its new cell and gene therapy manufacturing facility in Allendale, New Jersey. The new facility is the ...

January 21, 2020

Announcing Our Joint Development Agreement With Ori Biotech

For 20 years, Hitachi Chemical Advanced Therapeutics Solutions (HCATS) has helped clients to improve their cell-based therapy development and manufacturing processes. The client-focused mindset of our PCT global service platform allows our team to easily facilitate technology transfers, accelerate time to market, and reduce the costs and risks of clinical development programs. And now the future ...

January 13, 2020

apceth Starts Commercial Manufacturing of Zynteglo, bluebird bio's gene therapy for transfusion-dependent B-thalassemia

Munich, Germany, January 13, 2020 - apceth Biopharma GmbH, a subsidiary of Hitachi Chemical Co., Ltd. and a leading company for the manufacturing of cell and gene therapeutics, starts the commercial manufacturing of ZyntegloTM ▼, a product of bluebird bio, Inc. Today bluebird bio announced the market entry of its gene therapy Zynteglo in Germany, the first country globally where Zynteglo is ...

June 4, 2019

apceth Will Operate as the Commercial Manufacturer in Europe for Zynteglo, bluebird bio’s Gene Therapy for β-thalassemia

Munich, Germany, June 4, 2019 - apceth Biopharma GmbH, a leading company for the manufacturing of cell and gene therapeutics, will operate as the commercial manufacturer in Europe for ZyntegloTM, a product of bluebird bio. Yesterday the European Commission (EC) has granted conditional marketing authorisation for ZyntegloTM, a gene therapy for patients 12 years and older with transfusion-dependent ...

April 9, 2019

Hitachi Chemical Advanced Therapeutics Solutions and Saint-Gobain Announce Collaboration to Co-Develop and Commercialize Cell Therapy Manufacturing Technology

  April 9, 2019 - Hitachi Chemical Advanced Therapeutics Solutions, LLC (HCATS), a US subsidiary of Hitachi Chemical Co. Ltd. that engages in contract manufacturing and development of cell therapy products, and Saint-Gobain, a global leader in single-use solutions for the Biopharmaceutical industry, today announced a joint development agreement to co-develop and commercialize novel technology ...

All Posts